These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25737461)

  • 1. Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer?
    Levasseur N; Clemons M; Hilton J; Addison C; Robertson S; Ibrahim M; Arnaout A
    Minerva Chir; 2015 Jun; 70(3):181-93. PubMed ID: 25737461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant use of endocrine therapy in breast cancer.
    Macaskill EJ; Dixon JM
    Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant endocrine therapy in breast cancer.
    Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
    Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based neoadjuvant endocrine therapy for breast cancer.
    Dienstmann R; Bines J
    Clin Breast Cancer; 2006 Oct; 7(4):315-20. PubMed ID: 17092398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant endocrine therapy for locally advanced breast cancer.
    Ma CX; Ellis MJ
    Semin Oncol; 2006 Dec; 33(6):650-6. PubMed ID: 17145344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Endocrine Therapy: Who Benefits Most?
    Grossman J; Ma C; Aft R
    Surg Oncol Clin N Am; 2018 Jan; 27(1):121-140. PubMed ID: 29132556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
    Iwata H
    Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
    Harichand-Herdt S; Zelnak A; O'Regan R
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients.
    Geisler J; Smith I; Miller W
    J Steroid Biochem Mol Biol; 2012 Sep; 131(3-5):93-100. PubMed ID: 22207086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
    van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
    Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
    Wong ZW; Ellis MJ
    Oncology (Williston Park); 2004 Apr; 18(4):411-20; discussion 421, 424, 429 passim. PubMed ID: 15134351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer.
    Kolberg HC; Aktas B; Liedtke C
    Rev Recent Clin Trials; 2017; 12(2):67-72. PubMed ID: 28155606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant antihormonal treatment of women with breast cancer].
    Tuxen MK; Kamby C; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
    Tao Y; Klause A; Vickers A; Bae K; Ellis M
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):91-5. PubMed ID: 15994076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of endocrine adjuvant therapy for early breast cancer.
    Lønning PE
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S19-30. PubMed ID: 20374026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.